{
    "2021-06-04": [
        [
            {
                "time": "2023-11-07",
                "original_text": "Novartis' Neuroendocrine Tumors Targeted Radiotherapy Takes Small Hit on Clinically Relevant Overall Survival",
                "features": {
                    "keywords": [
                        "Neuroendocrine",
                        "Tumors",
                        "Targeted",
                        "Radiotherapy",
                        "Clinically",
                        "Relevant",
                        "Overall",
                        "Survival"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-11-07",
                "original_text": "Novartis (NVS) Announces Data on Radioligand Therapy at ASCO",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Radioligand",
                        "Therapy",
                        "ASCO"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-11-07",
                "original_text": "Novartis announces TabrectaÂ® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC",
                "features": {
                    "keywords": [
                        "Tabrecta",
                        "overall",
                        "survival",
                        "response",
                        "METex14",
                        "NSCLC"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-11-07",
                "original_text": "Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy",
                "features": {
                    "keywords": [
                        "checkpoint",
                        "inhibitor",
                        "tislelizumab",
                        "primary",
                        "endpoint",
                        "overall",
                        "survival",
                        "Phase",
                        "III",
                        "esophageal",
                        "cancer"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-11-07",
                "original_text": "Mesoblast (MESO) Q3 2021 Earnings Call Transcript",
                "features": {
                    "keywords": [
                        "Mesoblast",
                        "Q3",
                        "Earnings",
                        "Call",
                        "Transcript"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}